AnaptysBio Inc (ANAB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $55.20 (+0.25%), Market cap $2.02B, 52-week low–high $19.40 ~ $70.22.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indicatio
Financial statements, price targets, institutional (13F) holdings and related news for AnaptysBio Inc are updated in real time on BlackAll Trade.
AnaptysBio Inc trades at $55.20 (+0.25%). Real-time quotes and charts are available on BlackAll Trade.
AnaptysBio Inc has a market cap of about $2.02B.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Ro